Drug intelligence / Profile preview

ERXL201

Development stage: Preclinical
Lead developer: EnduRx Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems, Peptides

Overview

ERXL201 is a preclinical-stage peptide-directed polymeric nanoparticle being developed by EnduRx Pharmaceuticals for the treatment of atherosclerotic plaque. The drug is designed to target the macrophage component within atherosclerotic plaques to enable targeted delivery of therapeutic agents. This approach represents a non-lipid treatment strategy for atherosclerosis, aiming to reduce plaque burden and inflammation by specifically addressing the cellular drivers of the disease. It is currently in the preclinical development phase.

Beyond the preview

Go deeper on ERXL201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERXL201.

Explore the full profile